I

InDex Pharmaceuticals Holding AB
STO:FLERIE

Watchlist Manager
InDex Pharmaceuticals Holding AB
STO:FLERIE
Watchlist
Price: 45.3 SEK 1.59% Market Closed
Market Cap: 3.5B SEK
Have any thoughts about
InDex Pharmaceuticals Holding AB?
Write Note

InDex Pharmaceuticals Holding AB
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

InDex Pharmaceuticals Holding AB
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Accounts Receivables
kr700k
CAGR 3-Years
N/A
CAGR 5-Years
151%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Accounts Receivables
kr222.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Accounts Receivables
kr321.9m
CAGR 3-Years
50%
CAGR 5-Years
70%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Accounts Receivables
kr287.4m
CAGR 3-Years
59%
CAGR 5-Years
74%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Accounts Receivables
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

InDex Pharmaceuticals Holding AB
Glance View

Market Cap
3.5B SEK
Industry
Pharmaceuticals

InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

FLERIE Intrinsic Value
5.85 SEK
Overvaluation 87%
Intrinsic Value
Price
I

See Also

What is InDex Pharmaceuticals Holding AB's Accounts Receivables?
Accounts Receivables
700k SEK

Based on the financial report for Sep 30, 2024, InDex Pharmaceuticals Holding AB's Accounts Receivables amounts to 700k SEK.

What is InDex Pharmaceuticals Holding AB's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
151%

Back to Top